Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups

Author(s): Ayse Tan*, Serap Kizilkaya, Unzile Kelestemur, Atilla Akdemir and Yunus Kara

Volume 20, Issue 11, 2020

Page: [1368 - 1378] Pages: 11

DOI: 10.2174/1871520620666200410080648

Price: $65

Abstract

Background: Isoindole-1,3(2H)-dione derivatives are known to have cytotoxic effects on many cancer cells. The anticancer activity of these compounds varies depending on the substituents attached to them. Therefore, the effect of substituents is very important when determining the anticancer activities of molecules. We have recently reported an example of the substituent effect.

According to that work, the anticancer activity against HeLa, C6, and A549 cancer cell lines of isoindole- 1,3(2H)-dione compounds containing tert-butyldiphenylsilyl ether, azido, and hydroxyl groups was examined by our group. It was found that an isoindole-1,3(2H)-dione compound containing both tert-butyldiphenylsilyl ether group and azido groups showed higher anticancer activity than 5-fluorouracil and another isoindole-1,3(2H)- dione compound containing both azido and hydroxyl groups.

After we discovered that tert-butyldiphenylsilyl ether group in the skeletal structure of isoindole-1,3(2H)-dione exhibits anticancer activity against HeLa, C6, and A549 cancer cell lines, we wanted to examine the anticancer activities of different silyl ether groups, i.e., OTMS, -OTBDPS, and -OTBDMS groups, and also -OH and -Br groups, by comparing them with each other according to the structure–activity relationship.

Methods: All of the synthesized compounds were characterized by 1H and 13C NMR spectra, IR spectroscopy, and mass spectra measurements. The IC50 values of these compounds were calculated for all cancer cell lines and compared with each other and cisplatin, which is a platinum-containing chemotherapeutic drug. Molecular modelling studies were carried out using the MOE software package.

Results: It was found that compounds 13 and 16, containing both silyl ether (-OTBDMS) and -Br groups, showed higher anticancer activity than cisplatin against both Caco-2 and MCF-7 cell lines. Compounds 20 and 23 showed anticancer activity in MCF-7 cells and compounds 8, 9, 20, and 23 in Caco-2 cells. While compounds 20 and 23 have only a silyl ether (-OTMS) group, compounds 8 and 9 have only a -OH group. Molecular modelling studies indicated that compounds 8 and 13, as well as their analogs, may bind to the active site of hRS6KB1 (pdb: 4l3j), compound 11 may bind to the active site of human mTOR (pdb: 4jt5) and additionally, compounds 10-17 are expected to be both mutagenic and reactive according to the mutagenicity and reactivity calculations.

Conclusion: According to these results, the anticancer activities of isoindole-1,3(2H)-dione compounds (8 - 23) vary depending on the groups they contain and these groups affect each other's activities. Silyl ethers (-OTBDMS and -OTMS) and -OH and -Br groups in the skeletal structure of isoindole-1,3(2H)-dione can be regarded as anticancer agents. In this sense, compounds 13 and 16, containing both silyl ether (-OTBDMS) and - Br groups, may be regarded as alternative chemotherapeutic drugs. This work may lead to the synthesis of new isoindole-1,3(2H)-dione compounds containing different silyl ether groups and studies evaluating their anticancer activities or other biological properties.

Keywords: Isoindole-1, 3(2H)-dione, trimethylsilyl ether, tert-butyldiphenylsilyl ether, tert-butyldiphenylsilyl ether, MCF-7, Caco-2, molecular modeling.

« Previous Next »
Graphical Abstract

[1]
Ching, L.M.; Browne, W.L.; Tchernegovski, R.; Gregory, T.; Baguley, B.C.; Palmer, B.D. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br. J. Cancer, 1998, 78(3), 336-343.
[http://dx.doi.org/10.1038/bjc.1998.495] [PMID: 9703279]
[2]
McCluskey, A.; Walkom, C.; Bowyer, M.C.; Ackland, S.P.; Gardiner, E.; Sakoff, J.A. Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A. Bioorg. Med. Chem. Lett., 2001, 11(22), 2941-2946.
[http://dx.doi.org/10.1016/S0960-894X(01)00594-7] [PMID: 11677131]
[3]
Lima, L.M.; Castro, P.; Machado, A.L.; Fraga, C.A.M.; Lugnier, C.; de Moraes, V.L.G.; Barreiro, E.J. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg. Med. Chem., 2002, 10(9), 3067-3073.
[http://dx.doi.org/10.1016/S0968-0896(02)00152-9] [PMID: 12110331]
[4]
Li, M.; Sun, W.; Yang, Y.P.; Xu, B.; Yi, W.Y.; Ma, Y.X.; Li, Z.J.; Cui, J.R. In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells. Acta Pharmacol. Sin., 2009, 30(1), 134-140.
[http://dx.doi.org/10.1038/aps.2008.13] [PMID: 19098937]
[5]
Sabastiyan, A.; Suvaikin, M.Y. Synthesis, characterization and antimicrobial activity of 2-(dimethylaminomethyl) isoindoline-1, 3-dione and its cobalt (II) and nickel (II) complexes. Adva. Appl. Sci. Res., 2012, 3(1), 45-50.
[6]
Prado, S.R.T.; Cechinel-Filho, V.; Campos-Buzzi, F.; Corrêa, R.; Cadena, S.M.C.S.; de Oliveira, M.B.M. Biological evaluation of some selected cyclic imides: mitochondrial effects and in vitro cytotoxicity. Z. Natforsch. C J. Biosci., 2004, 59(9-10), 663-672.
[http://dx.doi.org/10.1515/znc-2004-9-1010] [PMID: 15540599]
[7]
Liao, H-F.; Su, S-L.; Chen, Y-J.; Chou, C-H.; Kuo, C-D. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem. Toxicol., 2007, 45(9), 1678-1687.
[http://dx.doi.org/10.1016/j.fct.2007.03.003] [PMID: 17442474]
[8]
Kok, S.H.; Hong, C.Y.; Kuo, M.Y.; Lee, C.H.; Lee, J.J.; Lou, I.U.; Lee, M.S.; Hsiao, M.; Lin, S.K. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol., 2003, 39(1), 19-26.
[http://dx.doi.org/10.1016/S1368-8375(01)00129-4] [PMID: 12457717]
[9]
Fan, Y-Z.; Fu, J-Y.; Zhao, Z-M.; Chen, C-Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. HBPD INT, 2007, 6(1), 72-80.
[PMID: 17287171]
[10]
Hong, C-Y.; Huang, S.C.; Lin, S-K.; Lee, J.J.; Chueh, L-L.; Lee, C-H.K.; Lin, J-H.; Hsiao, M. Norcantharidin-induced post-G(2)/M apoptosis is dependent on wild-type p53 gene. Biochem. Biophys. Res. Commun., 2000, 276(1), 278-285.
[http://dx.doi.org/10.1006/bbrc.2000.3341] [PMID: 11006118]
[11]
Hill, T.A.; Stewart, S.G.; Ackland, S.P.; Gilbert, J.; Sauer, B.; Sakoff, J.A.; McCluskey, A. Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg. Med. Chem., 2007, 15(18), 6126-6134.
[http://dx.doi.org/10.1016/j.bmc.2007.06.034] [PMID: 17606377]
[12]
Köse, A.; Bal, Y.; Kishalı, N.H.; Şanlı-Mohamed, G.; Kara, Y. Synthesis and anticancer activity evaluation of new isoindole analogues. Med. Chem. Res., 2017, 26(4), 779-786.
[http://dx.doi.org/10.1007/s00044-017-1793-1]
[13]
Chen, Y.N.; Chen, J.C.; Yin, S.C.; Wang, G.S.; Tsauer, W.; Hsu, S.F.; Hsu, S.L. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int. J. Cancer, 2002, 100(2), 158-165.
[http://dx.doi.org/10.1002/ijc.10479] [PMID: 12115564]
[14]
Lin, L-H.; Huang, H-S.; Lin, C-C.; Lee, L-W.; Lin, P-Y. Effects of cantharidinimides on human carcinoma cells. Chem. Pharm. Bull. (Tokyo), 2004, 52(7), 855-857.
[http://dx.doi.org/10.1248/cpb.52.855] [PMID: 15256708]
[15]
Tan, A.; Yaglioglu, A.; Kishali, N.; Sahin, E.; Kara, Y. Evaluation of cytotoxic potentials of some isoindole-1, 3-dione derivatives on HeLa, C6 and A549 cancer cell lines. Med. Chem., 2020, 16(1), 69-77.
[16]
Patiny, L.; Borel, A. ChemCalc: A building block for tomorrow’s chemical infrastructure. J. Chem. Inf. Model., 2013, 53(5), 1223-1228.
[http://dx.doi.org/10.1021/ci300563h] [PMID: 23480664]
[17]
Labute, P. Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins, 2009, 75(1), 187-205.
[http://dx.doi.org/10.1002/prot.22234] [PMID: 18814299]
[18]
Kazius, J.; McGuire, R.; Bursi, R. Derivation and validation of toxicophores for mutagenicity prediction. J. Med. Chem., 2005, 48(1), 312-320.
[http://dx.doi.org/10.1021/jm040835a] [PMID: 15634026]
[19]
Oprea, T.I. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des., 2000, 14(3), 251-264.
[http://dx.doi.org/10.1023/A:1008130001697] [PMID: 10756480]
[20]
Ranise, A.; Spallarossa, A.; Cesarini, S.; Bondavalli, F.; Schenone, S.; Bruno, O.; Menozzi, G.; Fossa, P.; Mosti, L.; La Colla, M. Structure-based design, parallel synthesis, structure−activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. J. Med. Chem., 2005, 48(11), 3858-3873.
[21]
Katzaklan, A., Jr; Steele, R.B.; Scigliano, J.J.; Hamel, E.E. Catalytic reactions. CA Patent 1,032,696A1. 1978.
[22]
Steele, R.B.; Katzakian, A., Jr Catalysts for the cleavage of oxirane by carboxylic acids. DE Patent 2,439,352A1. 1975.
[23]
Steele, R.B.; Scigliano, J.J.; Katzakian, A., Jr N-Hydroxyalkyl imides. DE Patent 2,357,936A1. 1974.
[24]
Tan, A.; Koc, B.; Kishali, N.; Sahin, E.; Kara, Y. Synthesis of new hexahydro-1H-isoindole-1,3(2H)-dione derivatives from 2-ethyl/phenyl-3a,4,7,7a-tetrahydro-1H-isoindole-1,3-(2H)-dione. Turk. J. Chem., 2016, 40(5), 830-840.
[http://dx.doi.org/10.3906/kim-1511-66]
[25]
Tan, A.; Bozkurt, E.; Kara, Y. Investigation of solvent effects on photophysical properties of new aminophthalimide derivatives-based on methanesulfonate. J. Fluoresc., 2017, 27(3), 981-992.
[http://dx.doi.org/10.1007/s10895-017-2033-2] [PMID: 28078631]
[26]
Tan, A.; Koc, B.; Sahin, E.; Kishali, N.H.; Kara, Y. Synthesis of new cantharimide analogues derived from 3-sulfolene. Synthesis-Stuttgart, 2011, 7, 1079-1084.
[27]
Larrosa, I.; Da Silva, M.I.; Gómez, P.M.; Hannen, P.; Ko, E.; Lenger, S.R.; Linke, S.R.; White, A.J.; Wilton, D.; Barrett, A.G. Highly convergent three component benzyne coupling: the total synthesis of ent-clavilactone B. J. Am. Chem. Soc., 2006, 128(43), 14042-14043.
[http://dx.doi.org/10.1021/ja0662671] [PMID: 17061883]
[28]
Galanski, M. Recent developments in the field of anticancer platinum complexes. Rec. Pat. Anticancer Drug Discov., 2006, 1(2), 285-295.
[http://dx.doi.org/10.2174/157489206777442287] [PMID: 18221042]
[29]
Sreedhar, A.S.; So, C.; Csermely, P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim. Biophys. Acta, 2004, 1697(1-2), 233-242.
[http://dx.doi.org/10.1016/j.bbapap.2003.11.027]

Rights & Permissions Print Cite
Article Metrics
10
© 2024 Bentham Science Publishers | Privacy Policy